Avere Therapeutics

NASDAQ: AVERE ↗~$0.3B (post-merger) MCAP

Avere Therapeutics is a clinical-stage immunology company developing drugs for autoimmune and inflammatory diseases. The company was formed from the former Akero Therapeutics team and entered the public markets via a reverse merger, also acquiring rights to a Hansoh Pharmaceutical drug for $120M.

Company Info

Sector:Immunology / Inflammation

Headquarters:South San Francisco, California, USA

Founded:2026

Website:www.avere-tx.com/

Upcoming Milestones & Key Dates

2026-Q4

Strategic

Pipeline expansion announcements post reverse merger

Clinical Development Pipeline

Hansoh-licensed compound

Target: Undisclosed

Autoimmune disease (undisclosed)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Leadership Team

TBD

CEO

TBD

Chief Scientific Officer

TBD

Chief Medical Officer

Careers & Job Openings

See all open roles

Multiple Departments

South San Francisco, California, USA

Apply Now →